One-carbon therapeutics AB management at ESMO to discuss the ODIN clinical phase 1/2 trial with potential clinical sites across Europe
One-carbon therapeutics AB is discussing the ODIN trial with several leading clinical sites at the upcoming ESMO meeting in Barcelona. The ODIN trial is a first-in-human, first-in-class clinical phase 1/2 trial with MTHFD1/2 inhibitor TH9619 in selected solid cancers.
